secwatch.observer — SEC 8-K summary
======================================

Issuer:     COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK:        0001267565
Form:       8-K
Filed at:   2023-01-04T23:59:59+00:00
Accession:  0001104659-23-000644
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Collegium provides 2023 guidance: rev $565-580M, adj EBITDA $355-370M, $100M buyback
--------------------------------------------------------------------------------

- Product revenue net expected $565-580M for 2023, up from ~$460M in 2022.
- Adjusted EBITDA $355-370M, growing >4x rate of adjusted operating expenses ($135-145M).
- Board authorized $100M share repurchase program through December 31, 2023.
- Xtampza ER gross-to-net expected 61-63% in 2023, down from >65% previously.
- Federal Circuit upheld Belbuca patents, blocking Alvogen generic entry until 2032.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267565/000110465923000644/0001104659-23-000644-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267565/000110465923000644/tm231443d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-000644

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer